Topics

Metastatic Hormone Refractory Prostate Cancer Pricing Market Access and Landscape 2019 [Published by First View Insight] Prices from USD $2125

05:10 EST 2 Feb 2020 | BioPortfolio Report Blog

Firstview Insight's Metastatic Hormone Refractory Prostate Cancer Pricing Market Access and Landscape 2019 provides country specific insights in order to estimate market potential for Metastatic Hormone Refractory Prostate Cancer based on the pricing and reimbursement scenario and perceived value drivers in different market archetypes. It gives a detailed picture of the disease landscape and unmet needs of different stakeholders existing in the current treatment paradigmThus it enables to identify and leverage on the commercial opportunities spanning across different lines of therapy. The report incorporates detailed analysis of the market development drivers as well as the preventing factors. The scope of the report covers an extensive estimation pertaining to the winning essentials and participant schemes through a presentation of the segmentation of market in the Pricing Market Access landscape.

Hormonerefractory prostate cancer is defined as 23 consecutive rises in prostatespecific antigen PSA levels obtained at intervals of greater than 2 weeks and/or documented disease progression based on findings from CT scan and/or bone scan, bone pain, or obstructive voiding symptoms. In a subgroup of patients, the PSA level does not rise at diagnosis or throughout the entire course of the disease.

Scope of the Report:

Market Access strategy for different payer archetypes

Segmentation and mapping of payers to different archetypes based on their specific criteria of assessment i.e. costeffectiveness, budget impact, clinical effectiveness. This would enable designing effective market strategy for reimbursement in these markets. It also covers the reimbursement decisions and benefit ratings of competitor drugs by different health technology assessment bodies in EU5,US and Japan.


Payer Policy changes and implications

Provides an overview of the changing payer preferences, concerns and evolving requirements. Informs about the payer policies impacting the prescription and uptake of particular product. Estimates the future payer environment and drivers of change.


Innovative pricing and funding mechanisms

With increasing pressure from payers and limitations in evidence development, many innovative payment mechanisms are being introduced such as outcome based reimbursement, annuity based funding etc. This section provides examples of such innovative models and feasibility of their application in a particular disease scenario.


Disease Overview

This report contains comprehensive overview of disease including disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends, as well as details about treatment algorithms and treatment guidelines


Epidemiology

This section encompasses information on the incidence and prevalence of disease in EU5, US Japan.


Existing and upcoming treatment landscape

Captures the evolution of treatment paradigm including the current and emerging drug therapies. Provides information on the clinical trial results, mechanism of action, route of administration, therapeutic positioning and regulatory milestones. It gives insight into the potential therapeutic targets for drug development.


Market Trends Unmet needs

This section of the report helps to understand the market trend and opportunities by analysing the impact of current therapies on the market, current and future unmet needs, drivers and barriers and demand of better technology. This is determined by analysing the impact of various factors such as mechanism of action, route, cost of therapy, patient segmentation, existing available treatments, compliance and need of the market, expected launch timelines, competitors, brand value and KOLs perception.

Major highlights of the report

Detailed analysis of existing and upcoming competitive landscape

HTA decisions and benefit ratings for :

NICE UK

GBA Germany

HASASMR and SMRFrance

AIFA Italy

AEMPS Spain

SMC Scotland

ICER US

Chuikyo Japan

Market archetyping and product positioning

Case studies on innovative funding models

Unmet need, major barriers and drivers across the industry:

Value story for achieving reimbursement and premium pricing in different markets

Original Article: Metastatic Hormone Refractory Prostate Cancer Pricing Market Access and Landscape 2019 [Published by First View Insight] Prices from USD $2125

NEXT ARTICLE

More From BioPortfolio on "Metastatic Hormone Refractory Prostate Cancer Pricing Market Access and Landscape 2019 [Published by First View Insight] Prices from USD $2125"

Quick Search

Relevant Topic

Endocrine Disorders
Endocrine disorders are grouped into two categories: hormone imbalance - when a gland produces too much or too little of an endocrine hormone development of lesions (such as nodules or tumors) in the endocrine system, which may or may not affect...